These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

967 related items for PubMed ID: 6949642

  • 1. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP, Preisler HD, Slocum H, Rustum YM.
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R.
    Cancer Res; 1989 Jan 01; 49(1):241-7. PubMed ID: 2908850
    [Abstract] [Full Text] [Related]

  • 3. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS, Chou TC, Andreeff M, Vale K, Clarkson BD, Young CW.
    Cancer Res; 1984 Feb 01; 44(2):825-30. PubMed ID: 6692380
    [Abstract] [Full Text] [Related]

  • 4. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 01; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S.
    Clin Cancer Res; 2002 Jul 01; 8(7):2123-33. PubMed ID: 12114412
    [Abstract] [Full Text] [Related]

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 7. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 8. Central nervous system (CNS) leukemia: the role of high dose cytarabine (HDAra-C).
    Morra E, Lazzarino M, Alessandrino EP, Inverardi D, Regazzi Bonora M, Pagnucco G, Orlandi E, Bernasconi P, Canevari A, Rondanelli R.
    Bone Marrow Transplant; 1989 Jan 15; 4 Suppl 1():101-3. PubMed ID: 2713552
    [Abstract] [Full Text] [Related]

  • 9. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U, Heinemann V, Wilmanns W.
    Anticancer Res; 1989 Jan 15; 9(1):119-24. PubMed ID: 2705739
    [Abstract] [Full Text] [Related]

  • 10. [Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences].
    Fukushima T, Ueda T, Kamiya K, Yoshida W, Tsutani H, Uchida M, Nakamura T, Kagawa D, Domae N.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan 20; 25(1):126-31. PubMed ID: 2324584
    [Abstract] [Full Text] [Related]

  • 11. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 Jan 20; 82(6):664-7. PubMed ID: 9499665
    [Abstract] [Full Text] [Related]

  • 12. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 Jan 20; 82(5 Suppl):19-22. PubMed ID: 9402749
    [Abstract] [Full Text] [Related]

  • 13. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar 20; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 14. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 15. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 16. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
    Pöttgen C, Stuschke M, Stüben G, Schmitz A, Schwechheimer K, Wacker HH, Rauhut F, Kleuker S, Wilhelm H, Grehl S, Fehlings T.
    Strahlenther Onkol; 2003 Sep 01; 179(9):626-32. PubMed ID: 14628129
    [Abstract] [Full Text] [Related]

  • 17. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S, Paydas S, Disel U, Sahin B.
    Am J Ther; 2006 Sep 01; 13(5):389-93. PubMed ID: 16988532
    [Abstract] [Full Text] [Related]

  • 18. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN, Herzig RH, Phillips GL, Lazarus HM, Greer JP, Stein RS, Ray WA, Herzig GP.
    Semin Oncol; 1987 Jun 01; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [Abstract] [Full Text] [Related]

  • 19. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
    Berman E, Raymond V, Daghestani A, Arlin ZA, Gee TS, Kempin S, Hancock C, Williams L, Stevens YW, Clarkson BD.
    Cancer Res; 1989 Jan 15; 49(2):477-81. PubMed ID: 2910465
    [Abstract] [Full Text] [Related]

  • 20. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE, Plunkett W, Linker CA.
    Cancer Res; 1991 Aug 15; 51(16):4141-5. PubMed ID: 1868435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.